Clinical Trial Update: Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

View source ↗

Summary

This clinical trial update reports recruitment for real-world use of Lutetium-177 Lu vipivotide tetraxetan in China for metastatic prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Prostate Cancer | Status: RECRUITING